ABSTRACT: Background. The primary purposes of this interdisciplinary consensus statement were to review the relevant indications for central neck dissection (CND) in patients with papillary thyroid cancer (PTC) and to outline the appropriate extent and relevant techniques required to accomplish a safe and effective CND. Methods. A writing group convened by the American Head and Neck Society (AHNS) Endocrine Committee was tasked with identifying the important clinical elements to consider when managing the central neck compartment in patients with PTC based on available evidence in the literature, and the group's collective experience. The position statement paper was then submitted to the full Endocrine Committee, Education Committee, and AHNS Council. Results. This consensus statement was developed to inform the clinical decision-making process when managing the central neck compartment in patients with PTC from the AHNS. This document is intended to provide clarity through definitions as well as a basic guideline from which to manage the central neck. It is our hope that this improves the quality and reduces variation in management of the central neck, facilitates communication, and furthers research for patients with thyroid cancer. Conclusion. This represents, in our opinion, contemporary optimal surgical care for this patient population and is endorsed by the American Head and Neck Society.
INTRODUCTION
Regional lymph node metastases from differentiated thyroid cancer (DTC) are present in the majority of patients with papillary thyroid cancer (PTC), and in a smaller proportion of patients with other follicular-derived cancer histotypes. [1] [2] [3] Although lymph node metastases from PTC are seen frequently, specific and detailed surgical guidelines devoted to their management do not currently exist outside of the broad American Thyroid Association (ATA) and National Comprehensive Cancer Network guidelines, 4, 5 and none has been offered or endorsed by any surgical organization. Optimizing patient outcomes in PTC management involves balancing the risk from treatment against the risk from disease, and decisions about when to perform a central neck dissection (CND), both therapeutic central neck dissection (rCND) and prophylactic central neck dissection (pCND), are made individually.
This consensus statement is intended to offer a more surgically explicit discussion of CND, focusing on the indications and extent of dissection required in patients with PTC, while balancing surgical risk and oncologic outcome from the perspective of the American Head and Neck Society (AHNS). Through this work, we seek to reduce unnecessary variation in the management of the central compartment and to clarify the limitations of the current best evidence to provide optimal surgical care for our patients.
MATERIALS AND METHODS
A writing group convened by the Endocrine Committee of the AHNS was tasked with identifying the important clinical elements to consider when managing the central *Corresponding author: N. Agrawal, Section of Otolaryngology -Head and Neck Surgery, The University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637. E-mail: Nishant.agrawal@uchicago.edu compartment in patients with PTC. Experts in thyroid cancer representing the fields of otolaryngology-head and neck surgery, endocrine surgery, and endocrinology were included. The entire writing group reviewed the specific goals of the consensus statement and participated in the outline development. The contents and controversial points of the proposed statements were reviewed by all authors and discussion continued until agreement could be reached. Draft statements were circulated among these members and their edits were incorporated. Once this iterative process was complete, a draft was then sent to the full writing panel for their commentary and input.
This consensus statement was developed within the framework of current ATA management guidelines to outline the relevant indications for CND, and the extent of dissection required based on the literature available at the time of writing. Additional input and recommendations were developed by the writing group to cover areas of uncertainty that guidelines do not address, or where existing evidence is insufficient. The present consensus statement was then submitted to the full AHNS Endocrine Committee for further feedback. After endorsement by the Endocrine Committee, it was reviewed by the AHNS Education Committee and by the AHNS governing council who made further edits and then endorsed it in its current form.
The literature used as the basis for our review was obtained by a PubMed search using the following terms: differentiated thyroid cancer; papillary thyroid carcinoma; central compartment; lymph node metastases; lymph node dissection; lymph node surgery; complications; hypocalcemia; recurrent laryngeal nerve; vocal fold paralysis; extralaryngeal nerve branching; and molecular markers. The majority of articles were from the year 2000 onward, excepting known important older articles, which were selectively included.
DISCUSSION

Statement 1
The lymph nodes of the central neck compartment (levels VI and VII) are divided into discrete subcompartments, based on anatomic location, which can be independently dissected during CND for PTC. These discrete nodal packets are the: (1) prelaryngeal (Delphian) lymph nodes; (2) pretracheal lymph nodes; (3) right paratracheal lymph nodes; and (4) left paratracheal lymph nodes.
The 2009 ATA consensus statement on the relevant anatomy and terminology of CND concluded that the central neck compartment includes levels VI and VII lymph nodes. 6 The boundaries of the level VI lymph nodes are defined superiorly by the hyoid bone, inferiorly by the sternal notch, laterally by the medial aspect of the carotid sheath, posteriorly by the prevertebral fascia, and anteriorly by the superficial layer of the deep cervical fascia. Level VII lymph nodes are those associated with the brachiocephalic vein and innominate artery. The inferior boundary of level VII, included as the lowest portion of the ATA-defined CND, is defined by the innominate artery on the right (at its point of tracheal crossing) and the corresponding axial plane on the left. The lymph nodes are further subdivided based on anatomic location. The prelaryngeal, pretracheal, and paratracheal (left and right) nodes are most commonly involved with PTC. Metastases to the retropharyngeal or retroesophageal nodes are less common. [7] [8] [9] Mediastinal lymph nodes located inferior to the innominate artery and caudal to the brachiocephalic vein are rarely involved in patients with existing central compartment lymph node metastases (Table 1) . 10 
Statement 2
Statement 2A. A CND implies comprehensive removal of the pretracheal and prelaryngeal lymph nodes, along with at least one paratracheal nodal basin.
Statement 2B.
A CND can be unilateral or bilateral depending if one or both paratracheal regions are dissected.
Statement 2C. The specific regions and nodal packets dissected as part of the CND should be clearly identified in the operative report. In addition, the indication for CND should be defined as therapeutic or prophylactic.
The extent of CND should be described as unilateral or bilateral and should indicate which side the dissection was performed unilaterally. Unilateral CND involves removal of the pretracheal and prelaryngeal lymph nodebearing tissue, along with unilateral (right or left) paratracheal lymph node removal. 6 Bilateral CND includes removal of the pretracheal, prelaryngeal, and bilateral paratracheal lymph node bearing tissue.
The use of consistent terminology when describing CND is advocated. 6 This includes defining the indication for CND as therapeutic or elective/prophylactic. Therapeutic dissection (rCND) involves removal of clinically apparent lymph node metastases based on preoperative radiographic or intraoperative demonstration of macroscopic disease (cN1). The pCND is defined as the removal of clinically uninvolved lymph nodes (cN0). The term "elective" dissection and "prophylactic" dissection may be used interchangeably.
Statement 3
Statement 3A. Approximately 35% of patients presenting with PTC have cN1 disease. The most common site of lymph node metastases from PTC is the central compartment. Up to 80% of patients presenting with cN0 disease (based on physical examination, preoperative imaging, and/or by inspection at the time of surgery) may harbor microscopically positive nodes.
Statement 3B. Lateral compartment lymph node metastases occur less frequently and usually subsequent to central compartment lymph node metastases. However, cases of skip metastases to the lateral compartment (with the central neck being negative) can occur in up to 18% of the patients, which occurs more commonly in superior pole tumors. At the time of initial surgery, approximately 35% of patients with PTC have cN1 disease and up to 80% of patients with cN0 disease have microscopic lymph node metastases. 3, [11] [12] [13] Thyroid cancer cells usually spread through the lymphatic system in a sequential fashion, initially to the lymph nodes of the central compartment, and then progressively to the lymph nodes of the lateral compartment and the superior mediastinum. 14 Although it is safe to consider the central compartment lymph nodes as the primary drainage for all thyroid cancers, skip metastases to the lateral compartment lymph nodes can occur in up to 18% of the patients. 13 Specifically, PTC arising in the upper pole of the thyroid has a higher propensity to demonstrate skip metastases to levels III and II of the lateral compartment. 15 
Statement 4
The anatomy of the right and left paratracheal regions is different. This has significance in the nodal distribution relative to the recurrent laryngeal nerve (RLN), and in the surgical complexity of the RLN dissection and nodal removal.
Because of the different positions of the right subclavian artery and aortic arch relative to the midline trachea, the right RLN ascends the right paratracheal region obliquely extending from lateral to medial (see Figures 1  and 2 ). In addition, because the innominate artery crosses ventral to the trachea, the right inferior paratracheal regional vascular anatomy is more ventral than the aortic arch on the left and so the right RLN initially travels more ventrally within the right paratracheal region than the left RLN in the left paratracheal region. This results in lymphatic tissue in the right paratracheal region being located both anterior and posterior to the right RLN. For the dissection of the right paratracheal region to be complete, the lymphatic tissue deep to the right RLN should ideally be removed. 16 This more dorsal region deep to the right RLN is of specific concern because it is a common and unfavorable place for disease recurrence. 17 To remove both the anterior and posterior lymph node components, the right RLN needs to be transposed. 18 The posterior paratracheal lymphatic tissue is then mobilized anteriorly and drawn under the RLN toward the lymph nodes that are caudal to the inferior thyroid artery. 19 The left RLN ascends the neck in general in a more strictly caudal-to-cranial direction in the tracheoesophageal groove 20, 21 (see Figure 1 ). The lymphatic tissue in the left paratracheal region is located anterior to the RLN and the esophagus, dorsal to the thymus, lateral to the trachea, and medial to the common carotid artery. 16 
Statement 5
Extralaryngeal branching of the RLN is common and increases the risk of nerve injury when present. The preponderance of motor innervation comes from the most anterior branch. Knowledge of the precise course, variations, and anomalies of the RLN will aid in avoidance of injury to the nerve during CND.
The RLN may branch before the laryngeal entry point in 30% to 78% of cases. [22] [23] [24] [25] [26] [27] About 60% of patients have some small branches of the RLN to the trachea, esophagus, or inferior constrictor muscle; however, only 20% to 30% have true extralaryngeal branches that enter the larynx (see Figure 2) . 23, 28, 29 Most laryngeal branches arise from the distal RLN segment, with 90% of the branching occurring superior to the intersection of the RLN and the inferior thyroid artery. 25 Only 5.4% of nerves are found to branch inferior to the level of the RLN and inferior thyroid artery crossing. 30 Thus, extralaryngeal branches of the RLN, when present, usually exist at the level of the ligament of Berry and are usually not present inferior to the inferior thyroid artery. 31 The occurrence and pattern of RLN branching vary from side to side and within the same patient. 25, 32, 33 Precise anatomic knowledge of the extralaryngeal bifurcation pattern of the RLN has important surgical implications. Dividing a sensory ramus (typically in the posterior division) has no immediate critical outcome, although it may contribute to postoperative dysphagia; however, transection of a motor ramus (typically in the anterior division) could cause laryngeal paralysis. 34 Branched RLNs are twice as likely to have transient vocal fold paralysis postoperatively (15.8%) than nonbranched RLNs (8%). 35 Casella et al 36 suggested an even more increased rate of vocal fold paralysis from 7 to 12 times that of patients with nonbranched RLNs.
Statement 6
The prognostic impact of central compartment PTC nodal disease results primarily in an increased risk of subsequent nodal recurrence, not on survival, in the majority of patients. This increased risk of nodal recurrence resides almost exclusively in clinically apparent nodal disease and not in microscopically positive nodal disease.
Two large population-based studies have demonstrated an increased mortality rate with regional lymph node metastases from DTC. 37, 38 However, this effect was more evident in patients with follicular thyroid cancer, patients with PTC over the age of 45 years, and with bulky nodes. 1, [38] [39] [40] If the effect of lymph node metastases on survival is present, it is probably small and most significant in older patients. 4 Evidence from the literature suggests that the predominant prognostic issue with nodal metastasis is in increased risk of subsequent nodal recurrence.
The characteristics of the lymph node metastases can help further define the risk of recurrence to the patient, especially in those patients with clinically apparent metastasis, multiple metastases, larger metastases, and/or extracapsular nodal extension, 39 ,40 compared with those with more limited microscopic nodal disease, which are associated with much lower rates of recurrence. [41] [42] [43] The prognostic importance of nodal disease in PTC seems to be centered on detection and treatment of cN1 disease. The presence of clinically apparent central neck nodal disease has been shown to be a robust age-independent predictor of overall survival and nodal recurrence. 44 Despite occult lymph node micrometastases being found in the central compartment of the neck in 38% to 80% of patients with PTC, the median rate of recurrence for patients with clinically node-negative disease is 2%, whether or not a pCND is performed. 45, 46 This finding suggests that most micrometastases remain dormant and infrequently develop into clinically significant disease, or alternatively that levothyroxine (T4) suppression and/or radioactive iodine ablation controls micrometastatic nodal disease.
Statement 7
Routine pCND is generally not recommended at the time of initial surgery for PTC. Thyroidectomy alone is appropriate for small (T1 or T2), noninvasive, and cN0 PTC. A pCND might be considered for larger (T3 or T4) tumors or in cases with N1b disease.
The value of routine pCND for cN0 disease remains unproven. This issue is compounded by the fact that no randomized controlled trial exists to evaluate pCND for the treatment of PTC. 47 However, the value for an individual patient depends upon the utility of the staging information to the multidisciplinary treatment team in specific patient circumstances and the skill and experience of the surgeon. 48, 49 The controversy over whether to perform a pCND also relates to the differing interpretations of existing data. Based on imperfect data, pCND has been suggested to improve disease-specific survival, 50 reduce rates of local recurrence, 51, 52 lower postoperative thyroglobulin levels, 51, 53 and provide accurate staging to help modify the indication for radioactive iodine ablation and dosing. [54] [55] [56] [57] Nevertheless, in several studies, pCND has shown no improvement in long-term patient outcome, although increasing the likelihood of morbidity, including hypoparathyroidism and RLN injury. 44, 55, [58] [59] [60] [61] [62] [63] [64] [65] The potential for significantly increased rates of these complications in lower-volume surgical venues is high.
Temporary hypoparathyroidism after CND occurs in 14% to 40% of cases in high volume centers. 61, 66 This high incidence of temporary hypoparathyroidism is likely because of the increased incidence of parathyroid autotransplantation and inadvertent removal of the parathyroid glands during dissection. Although reports are mixed regarding the incidence of permanent hypoparathyroidism, a meta-analysis performed by Chisholm et al 60 reported a 1.2% incidence, as defined by the requirement for calcium supplementation surpassing the 6-to 12-month period postoperatively. It should be emphasized that the studies used in this metaanalysis come from experienced/high-volume centers, so the rate of permanent complications, particularly permanent hypoparathyroidism, is likely to be significantly higher in nonspecialized/low-volume centers.
Other complications include injury to the RLN or to the external branch of the superior laryngeal nerve, which occurs in 1% to 2% of patients. 67 However, in experienced hands, the addition of CND to total thyroidectomy for the treatment of thyroid cancer has not been shown to increase permanent nerve injury rates. 60 Recent ATA recommendations for CND should be interpreted in light of available surgical expertise. 4 Several researchers have found that high-volume surgeons had 75% fewer complications related to thyroid surgery than low-volume surgeons (4.3% vs 16.1%). 68, 69 However, no similar comparative studies are available for outcomes related to CND.
Statement 8
The decision to perform pCND requires a multidisciplinary team decision-making process that includes the patient, surgeon, and endocrinologist weighing the risks and benefits individually in each case.
The patient must be aware of the risks associated with pCND, and the fact that pCND has not been shown to provide any clear benefit in long-term patient outcome. The surgeon's experience and complication rates also need to be taken into account and should be disclosed to the patient.
A pCND may be considered if: (1) the judgment of the multidisciplinary treatment team is that the patient is at high risk for recurrence despite the absence of cN1 disease (ie, older or very young age, larger tumor size [T3 or T4], multifocal disease, extrathyroidal extension, or known lateral node metastases); (2) the information obtained from pCND is felt of importance to inform the decision regarding use of adjuvant radioactive iodine therapy or thyroid-stimulating hormone-suppressive thyroxine therapy; and (3) ipsilateral clinically apparent lateral neck disease (cN1b) is present and is being targeted with lateral neck dissection.
It is important to note that the need for pCND is a decision the multidisciplinary team must make in each case, weighing the risks and benefits individually, considering the status of the contralateral RLN and parathyroid glands, and complications of previous treatment modalities, which may increase the technical difficulty of operating in this region. Ultrasound, cross-sectional imaging, and fine-needle aspiration (FNA) of the paratracheal nodes may help in this decision-making process, in select cases.
The average rate of recurrence for patients whose disease is judged at presentation to be cN0 ranges from 0% to 9% with an average of 4%. 3 Interestingly, patients with cN0 disease who have microscopic cervical lymph node metastases identified only by pCND (microscopic pN1) have a similar low risk of recurrence that ranges from 4% to 11.5% with an average of 6%. Because microscopic nodal positivity occurs frequently, pCND often converts patients from cN0 to pathologic N1a, upstaging disease in many patients over 45 years of age from the American Joint Committee on Cancer stage I to stage III. 51, 54, 55, 58, 59 However, microscopic nodal positivity does not carry the same recurrence risk of cN1 disease. 3 Thus, microscopic nodal upstaging may lead to excess radioactive iodine utilization, and, possibly, unnecessarily intense monitoring.
For low-risk and intermediate-risk patients with small (T1 or T2), noninvasive, cN0 disease, the balance of risk and benefit may favor close intraoperative inspection of the central compartment, with the plan adjusted to include CND only in the presence of cN1 disease. 4 Although ipsilateral pCND is advised for aggressive PTC variants, such as tall cell, diffuse sclerosing, and insular variants, information about tumor differentiation/grade is usually not known preoperatively.
A pCND can be considered in patients with prognostic features associated with an increased risk of metastasis and recurrence (ie, older or very young age, larger tumor size [T3 or T4], multifocal disease, extrathyroidal extension, or known lateral node metastases). 48, 51, 53 Patients with clinically apparent metastases in the lateral neck compartment who are undergoing lateral neck dissection can be considered for ipsilateral pCND. This is supported by a study that found that 83% of patients with positive nodes in the jugular chain had occult metastases in the ipsilateral paratracheal compartment, even when ultrasound of the paratracheal region was negative for metastases. 70 In another study, the rate of occult contralateral central compartment metastases was relatively high (34.3%) in patients with multifocal primary tumor and lymph node metastases in all ipsilateral neck levels. 71 These findings suggest that at least unilateral pCND may also be appropriate in addition to the lateral neck dissection.
Statement 9
None of the current molecular markers, including Btype Raf (BRAF), have been demonstrated to be clear, independent prognostic indicators; therefore, they should not impact the decision for pCND.
The presence of a BRAF V600E mutation has been associated in many studies with the aggressiveness of PTC (extrathyroidal invasion, lymph node metastasis, and advanced stage) and also with disease-specific mortality when associated with other aggressive features, such as extrathyroidal extension. 72, 73 However, BRAF V600E mutation analysis offers a very low positive predictive value (28%) for disease recurrence. 74 The clinical significance of RAS mutations in thyroid cancer is controversial; some reports show that RAS mutations are associated with tumor aggressive phenotypes and poor prognosis, 75, 76 whereas others have not confirmed this association. In fact, the recent newly designated benign neoplastic entity of noninvasive follicular thyroid neoplasm with papillary-like nuclear features is typically RAS-positive. 77 Similarly, RET/PTC rearrangements are associated in some reports with lymph node metastasis and extrathyroidal extension, 78 but with a better prognosis in other studies. 79, 80 Paired box gene (PAX)8-proliferator-activated receptors gamma (PPARg) rearrangements have been associated with multifocality of the tumors and vascular invasion, conferring an invasive potential. [81] [82] [83] Others have found that PAX8-PPARg rearrangements in thyroid nodules predict follicular-pattern carcinomas. 84 Despite this, the consistent detection of PAX8-PPARg rearrangements in benign tumors hinders its value as a prognostic molecular marker. 85 Two other molecular markers that seem to confer an increased risk of tumor recurrence and tumor-related mortality are the tumor protein p53 (TP53) and telomerase reverse transcriptase (TERT) mutations. TP53 mutations have been known to occur most often in poorly differentiated and anaplastic thyroid cancers. However, more recent broad genotypic analyses identified TP53 mutations (often at low copy numbers) in 3.5% of welldifferentiated PTC and 11% of well-differentiated follicular thyroid carcinomas. 86 TERT mutations are found in 7% to 22% cases of PTC and 14% to 17% cases of follicular carcinoma, but with a significantly higher prevalence in poorly differentiated thyroid cancer, [87] [88] [89] [90] and in PTC carrying BRAF mutation. 87, 88 In the largest reported series by Melo et al, 87 TERT mutation was found to be an independent predictor of decreased disease-free survival and overall survival for DTC. Furthermore, the combination of a TERT mutation and a BRAF mutation within the same tumor was associated with a high risk of structural disease recurrence. 91 These results suggest that these molecular markers may be helpful for risk stratification of thyroid cancer and provide significantly more accurate risk assessment than BRAF mutational status taken in isolation, but at this time are not accurate to predict the necessity of pCND. 92 
Statement 10
Statement 10A. Therapeutic CND should accompany total thyroidectomy to provide clearance of clinically apparent/ macroscopic nodal disease in patients with cN1 disease in the central compartment based on: (1) preoperative physical examination; (2) preoperative radiographic evaluation; or (3) intraoperative inspection.
Statement 10B. The extent of CND can be either unilateral or bilateral. Bilateral dissection is required when cN1 disease is present in both paratracheal regions, and only when there is a definitive benefit to be achieved given the potential for both hypocalcemia and significant airway complications through bilateral RLN injury.
A unilateral CND is preferred in cases of disease confined to one paratracheal region to minimize the risk to bilateral RLNs and parathyroid glands.
The role of CND for treatment of thyroid cancer is well accepted for cN1 disease. 6, 55, 59, 93 The rationale for a therapeutic CND at the time of thyroidectomy is to comprehensively remove all grossly evident nodal disease, along with any adjacent subclinical disease, to minimize risk of morbidity from reoperation for clinically evident disease initially undertreated. Goals of resection of clinically evident nodal metastases include reducing the development of recurrent disease and improving survival. 38, 93 A number of studies suggest that bilateral comprehensive CND may be associated with higher morbidity, primarily RLN injury, and transient hypoparathyroidism, with no reduction in recurrence. 61, 63, 94 Pereira et al 95 found that morbidity of CND correlated with the number of nodes resected, thymectomy, and incidental parathyroidectomy.
Nevertheless, the extent of CND should be adjusted depending on the surgeon's judgment of procedural safety as it relates to scarring and distortion of anatomy, from previous surgery or adjuvant treatment, and the perception of impending complications. 4 
Statement 11
Vigilant assessment is required both preoperatively (central and lateral) and intraoperatively (central) to accurately detect cN1 disease requiring dissection.
Ultrasound of the thyroid and bilateral cervical lymph node compartments (levels I-VI) is recommended in all patients with suspicious or diagnostic lesions of thyroid malignancy as the initial mapping study. Ultrasound assessment should be augmented by cross-sectional imaging (usually CT with contrast) if there is any evidence of an invasive primary, bulky or widely distributed nodal disease, nodes that extend inferiorly and cannot be fully evaluated by ultrasound, or if significant central neck nodal disease is suspected.
High-resolution ultrasound evaluation of bilateral cervical lymph node compartments should be performed routinely in the evaluation of patients with lesions suspicious for thyroid malignancy to guide a complete resection of the primary tumor as well as a compartment-oriented dissection of affected lymph node basins as necessary. 96 This will also facilitate patient counseling regarding surgical risks, because the addition of central or lateral neck dissection to total thyroidectomy is accompanied by a higher morbidity risk profile.
Although preoperative neck ultrasound is significantly more sensitive for the detection of abnormal lateral neck lymph nodes than central neck lymph nodes, 97 it is generally accepted that high-resolution ultrasound is often able to detect clinically significant nodal disease in the central neck compartment in the presence of the thyroid, and support conservative management of the central neck compartment in the absence of abnormal findings, at least when combined with careful intraoperative central compartment inspection. 44, 96 Ultrasound-guided FNA biopsy can then be used to confirm the presence or absence of malignancy by cytology analysis, if an operative intervention is to be planned. In addition, thyroglobulin (Tg) measurement from the FNA needle washout has been shown to improve the sensitivity of ultrasound FNA cytology, even in the presence of circulating anti-Tg antibodies. 98 Preoperative ultrasound may provide insight into the need for further cross-sectional imaging before surgery (Table 2) . CT imaging of the neck is optimized by iodinated contrast, although this advantage must be balanced against the impact the iodine load will have in causing a variable delay in postsurgical adjuvant radioactive iodine scans or therapy. 96 Non-contrast-enhanced CT is usually inadequate in defining neck structures, and, thus, its utility is limited to gross evaluation of the extent of mediastinal disease. MRI with gadolinium is a feasible alternative that avoids the use of iodine, but may be less informative to surgeons as compared to CT in the central and lateral neck compartments because of motion artifact arising from swallowing and respiration.
Statement 12
Even in the absence of preoperatively apparent cN1 disease, surgeons must assess all of the central neck subcompartments intraoperatively through visualization, inspection, and palpation to make sure that macroscopic nodal disease is appropriately detected and, therefore, resected.
Intraoperative inspection of central compartment lymph nodes is another technique to detect clinically involved lymph nodes requiring CND. Although it is well accepted that this technique underestimates the presence of pathologically detected nodal metastases, 99, 100 even in experienced hands, the need for CND can be accurately determined based on a combination of preoperative ultrasound and intraoperative inspection of the central compartment lymph nodes. 101 Sentinel lymph node biopsy shows an inconsistent pattern of nodal spread, and, therefore, does not seem to be readily transferable to thyroid surgery. 102 Similarly, the role for frozen section evaluation of sampled lymph nodes to identify Clinical or ultrasound evidence of an invasive primary thyroid malignancy (ie, irregular margins between the primary tumor and the aerodigestive tract or major vessels of the neck Presence of a large primary tumor Presence of bulky (>3 cm) nodal disease incompletely imaged with ultrasound (posteriorly or inferiorly located) Presence or extension of nodal disease into the mediastinum, retrotracheal, or parapharyngeal and retropharyngeal regions, incompletely imaged with ultrasound Suspicion of RLN tumor invasion (ie, vocal fold paralysis) Mass fixation to surrounding structures Absence of an experienced ultrasound practitioner in evaluating cervical lymph nodes Abbreviation: RLN, recurrent laryngeal nerve.
metastatic disease requiring CND remains uncertain. 103 Coexisting lymphocytic thyroiditis can add to the complexity of central compartment assessment because of the frequent presence of inflammatory lymphadenopathy.
Statement 13
Focal "berry picking" of only clinically involved lymph nodes without a compartmental dissection leads to higher rates of recurrence and should be abandoned.
Central neck dissection, either elective or therapeutic, is a comprehensive compartmental dissection and is distinguished from "berry picking" of only clinically involved lymph nodes. 6 Because of the increased risk of recurrence with focal node plucking or berry picking techniques, compartmental dissection is recommended. 95, [104] [105] [106] Typically, the number of nodes in the paratracheal regions ranges from 3 to 30 in number. 107 Pereira et al 95 has shown CND is usually associated with an average of 8.4 nodes on pathologic examination. The yield of metastatic lymph nodes in the central neck is significantly related to the number of lymph nodes in the CND and also is likely related to the extent of pathologic examination. 3, 54 The total number of lymph nodes removed is inversely related to postoperative serum Tg levels, and greater rates of athyroglobulinemia are achieved with a more comprehensive nodal dissection, 108 although thyroid remnant tissue also impacts significantly on postoperative Tg levels.
Statement 14
Intraoperative nerve monitoring (IONM) is useful during CND given its ability to: (1) map and localize the RLN and the external branch of the superior laryngeal nerve; (2) aid in dissection once the nerves are identified, and in elucidation of presence, mechanism, and site of nerve injury; and (3) to prognosticate postoperative nerve function allowing for intraoperative surgical decision changes to minimize the chances of bilateral nerve paralysis.
It is well demonstrated that RLN injury rates are lower when the nerve is routinely visualized as compared with surgeries in which the nerve is simply avoided. [109] [110] [111] Neural mapping via IONM is associated with rates of nerve identification between 98% and 100%, including nerves that are regarded as difficult to identify visually because of complex anatomy. 112, 113 A randomized study also showed significant improvement in time for RLN identification with IONM. 114 Although IONM is helpful in terms of neural identification and is a useful adjunct in neural dissection and ligament of Berry dissection, 115 the main function of IONM is the intraoperative prediction of postoperative function. 116 Blunt and stretch injuries to the nerve may not always be visibly detectable, and a nerve that seems structurally intact is not necessarily functional. Studies have shown that only 10% to 14% of injured nerves during surgery are visually identified as being injured. 117, 118 Snyder et al 119 also suggested that the majority of nerves injured are judged to be visually intact at surgery. Thus, visual examination is clearly insufficient to prognosticate postoperative RLN function.
In comparison, studies have shown that postoperative neural function prediction with IONM is associated with high negative predictive values ranging from 92% to 100%. 120, 121 The predictive ability of nerve monitoring is particularly important in bilateral thyroid surgery because both RLNs are placed at risk with one surgery. A loss of signal on the first operated side allows for rational change in operative strategy. When this technique was applied, complete avoidance of bilateral nerve paralysis was achieved, whereas if the second side was operated on after first side loss of signal, 19% of patients developed bilateral vocal fold paralysis. 122 
Statement 15
The parathyroid glands should be preserved with an intact vascular pedicle whenever possible during CND, especially the superior parathyroid glands.
The inferior parathyroid glands are at risk during paratracheal dissection, whereas the superior parathyroid glands can more easily be preserved, even in extensive paratracheal dissection, because of their more superior position. The inferior parathyroid gland should be searched for and may be reflected away with the vascular pedicle allowing for paratracheal dissection with inferior parathyroid gland preservation. If after dissection, the parathyroid gland appears nonviable and dusky, or there is interference with appropriate compartmental dissection, autotransplantation (after mincing it in small 12-mm pieces) into the ipsilateral sternocleidomastoid muscle should be undertaken. 123, 124 Generally, this implies that the dissection on the contralateral side would be somewhat less aggressive to prevent at least transient hypoparathyroidism.
A final careful inspection of the paratracheal specimen before passing it off the sterile surgical field for pathology is encouraged to inspect for any parathyroid glands within the specimen. Suspect parathyroid glands should be dissected free from surrounding nodal tissue, confirmed through frozen section biopsy to be parathyroid gland, and then autotransplanted into the ipsilateral sternocleidomastoid muscle.
It is crucial to identify the most reliable early determinants of hypocalcemia to help surgeons distinguish those patients who are at low risk for developing hypocalcemia from those who need supplementation therapy and possibly inpatient observation.
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Statement 16
Communication of intraoperative findings and postoperative care from the surgeon to the other multidisciplinary collaborators of the patient's thyroid cancer care team is critical for individualized risk stratification, subsequent therapy, and monitoring approaches that are often jointly managed in the postoperative setting.
Communication about the operative course is a standard surgeon responsibility, but should be optimized to report details that can influence postoperative management and surveillance. Important components of the operative report include 129 : (1) surgical anatomic findings, including IONM nerve signal information, as well as anatomic status of the RLN and parathyroid glands; and (2) surgical disease findings, including evidence for extrathyroidal extension, completeness of tumor resection (R0, R1, or R2 resection), presence, and distribution of nodal disease. Important postoperative details to communicate include: postoperative status, including voice and laryngeal assessment, dated laboratory data regarding serum calcium and parathyroid hormone levels, need for calcium and/or vitamin D supplementation, and the surgical pathology report with results of molecular prognostic markers if utilized.
As the multidisciplinary team remains engaged in the patient's pursuant care, communication concerning the patient's postoperative T4 dosing, Tg levels, any subsequent results of adjuvant radioactive iodine use, the initial estimates of risks of recurrence and disease-specific mortality, and the long-term care plan, is very appropriate.
CONCLUSIONS
This consensus statement has been developed to inform clinical decision-making when managing the central neck compartment in patients with PTC. Clinically apparent lymph node metastases in the central compartment should be treated with a comprehensive compartmental CND. In general, however, pCND is appropriate only in specific circumstances outlined in this statement. Even in these cases, given the risk of RLN injury and hypoparathyroidism, it may be more appropriate for experienced surgeons to perform rCND for the minority of patients who experience a recurrence in the central neck compartment, than for an inexperienced surgeon to perform routine pCND. Although patients with aggressive thyroid cancer variants, advanced primary tumors, or clinically involved lateral neck nodes can be considered for unilateral pCND, the balance between the risks and benefits may favor total thyroidectomy alone for patients with clinically nodenegative PTC. Surgeons must carefully audit their results and their patients' short-term and long-term outcomes when performing this procedure and caution should be exercised before routine implementation of CND. This statement represents, in our opinion, contemporary optimal care for this patient population.
